This discrepancy with higher CRP levels being associated with increased myosteatosis but lower SAT and IMAT has already been reported in the general population [39], leading us to hypothesise that the inflammatory state may favour a smaller decrease of the PMD in COVID-19 survivors as well. The gene discussed is CRP; the disease is COVID-19.